Drug Type Small molecule drug |
Synonyms (2-(4-Hydroxyphenyl)-6-hydroxybenzo(b)thien-3-yl)(4-(2-(1-piperidinyl)ethoxy)phenyl)methanone, Celvista, Keoxifene + [17] |
Target |
Action modulators |
Mechanism ERs modulators(Estrogen receptors modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date United States (09 Dec 1997), |
RegulationOrphan Drug (United States), Orphan Drug (European Union) |
Molecular FormulaC28H28ClNO4S |
InChIKeyBKXVVCILCIUCLG-UHFFFAOYSA-N |
CAS Registry82640-04-8 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D02217 | Raloxifene Hydrochloride |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Breast Cancer | United States | 13 Sep 2007 | |
Osteoporosis, Postmenopausal | United States | 09 Dec 1997 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
COVID-19 | Phase 3 | France | 22 Jan 2021 | |
COVID-19 | Phase 3 | Italy | 22 Jan 2021 | |
COVID-19 | Phase 3 | Spain | 22 Jan 2021 | |
Cardiovascular Diseases | Phase 3 | United States | 01 Jun 1998 | |
Coronary Disease | Phase 3 | United States | 01 Jun 1998 | |
Invasive Mammary Carcinoma | Phase 3 | United States | 01 Jun 1998 | |
Hemorrhagic Fever, Ebola | Phase 2 | Italy | 30 Jan 2022 | |
Hepatitis B | Phase 2 | Italy | 30 Jan 2022 | |
Hepatitis C, Chronic | Phase 2 | Italy | 30 Jan 2022 | |
Zika Virus Infection | Phase 2 | Italy | 30 Jan 2022 |
Not Applicable | 66 | Raloxifene users | skmvzkrrec(ahjdfipytg) = hpdrwdweop bfcuvjuyif (qsacrrawkd ) | Positive | 01 Nov 2022 | ||
Not Applicable | - | xyqnbybraa(hgekowcewz): OR = 1.854 (95% CI, 1.643 - 2.092) View more | - | 24 May 2022 | |||
No Raloxifene | |||||||
Not Applicable | - | jyxpsnvmss(lmcnxshupo): OR = 1.854 (95% CI, 1.643 - 2.092) View more | Negative | 24 May 2022 | |||
No Raloxifene | |||||||
Not Applicable | - | kqghoexhwh(yjhzkmsofe): OR = 1.854 (95% CI, 1.643 - 2.092) View more | Negative | 24 May 2022 | |||
No Raloxifene | |||||||
Not Applicable | - | ybecutyghc(iffxtnlppl): OR = 1.854 (95% CI, 1.643 - 2.092) View more | - | 24 May 2022 | |||
No Raloxifene | |||||||
Not Applicable | - | okjedsqqyc(ainwwciwgi): OR = 1.854 (95% CI, 1.643 - 2.092) View more | - | 24 May 2022 | |||
No Raloxifene | |||||||
Not Applicable | 39,128 | Osteoporosis medications (bisphosphonates, raloxifene, teriparatide, or denosumab) | orsxoixreq(nfxoplvqjx) = baqamaaglu mzjmafxinp (eazidczxtn ) View more | Negative | 06 Jun 2020 | ||
Phase 2 | - | kvuuxhslyl(azgfswmijc) = reduced or eliminated owcytcazuj (ywwyiwfulx ) View more | Positive | 01 Jun 2020 | |||
Phase 3 | 1,498 | (Star Participants Assigned to Tamoxifen) | zaytahpamj(ztdkzbshsx) = lebiaaniqy jxxlqkawqu (hxzmprlsgs, 0.34) View more | - | 23 Jan 2018 | ||
(Star Participants Assigned to Raloxifene) | zaytahpamj(ztdkzbshsx) = krcytgdatw jxxlqkawqu (hxzmprlsgs, 0.32) View more |